パーキンソン病　実践診療マニュアル　第2版

出版社： 中外医学社
著者：
発行日： 2018-10-20
分野： 臨床医学：内科  >  脳神経科学/神経内科学
ISBN： 9784498228535
電子書籍版： 2018-10-20 （2版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,060 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,060 円(税込)

購入する

商品紹介

パーキンソン病患者は増加の一途をたどり，非専門医でも日常的に診断・治療を行う機会が増えてきた．そのような現状を踏まえ，本書ではパーキンソン病を含む運動障害を専門とはしない医療従事者，研修医をターゲットに，その病態や診断，治療法，ケアまでを平易に解説．エキスパートの診療を再現した．改訂第2版では「パーキンソン病診療ガイドライン2018」の内容を反映．実践的な最新知識を得られる心強い1冊．

目次

  • ■I　パーキンソン病とはどのような病気か
    　■1．パーキンソン病の病態
    　　A. パーキンソン病発症のメカニズム
    　　B. ドパミンと運動制御のメカニズム
    　　C. 大脳基底核回路とパーキンソン病の運動症候
    　■2．わが国におけるパーキンソン病診療の現状と課題

    ■II　診断について
    　■1．問診と神経診察からいかにパーキンソン病の診断に迫るか？
    　　A. パーキンソン病の運動症状
    　　B. 運動症状と非運動症状
    　　C. パーキンソン病の新しい診断基準
    　■2．補助検査
    　　A. 嗅覚検査
    　　B. 自律神経系の検査
    　■3．鑑別診断上問題となる主な疾患
    　　A. PDと鑑別を要する主な疾患

    ■III　主なパーキンソン病治療薬のまとめ
    　■1．ドパミン系薬剤
    　　A. ドパミン系薬剤の開発
    　　B. L-ドパ
    　　C. デュオドーパＲ 治療
    　　D. ドパミンアゴニスト（DA）
    　　E. MAO-B（monoamine oxidase-B）阻害薬
    　　F. COMT（catechol-O-methyltransferase）阻害薬
    　■2．非ドパミン系薬剤
    　　A. 抗コリン薬
    　　B. 塩酸アマンタジン（シンメトレルＲ）
    　　C. ゾニサミド（トレリーフＲ）
    　　D. ドロキシドパ（ドプスＲ）
    　　E. アデノシン受容体拮抗薬

    ■IV　初期治療
    　■1．説明と同意
    　　「パーキンソン病はどのような治療があるのでしょうか？」
    　　「パーキンソン病は死ぬ病気ですか？」
    　　「この病気は認知症になりますか？」
    　　「この病気は遺伝しますか？」
    　　「パーキンソン病によい食べ物やサプリメントはありますか？
    　　　　あるいは食べないほうがよいものはありますか？」　
    　　「薬を飲んだらかえって悪くなると聞いたことがありますが本当ですか？」
    　　「運動はしてよいのですか？」
    　　「家族が気をつけることはありますか？」
    　■2．治療のタイミング
    　■3．治療法の選択
    　　　Case Study

    ■V　進行期治療
    　■1．運動合併症
    　　A. 運動合併症の病態
    　　B. 運動合併症とその治療戦略
    　　C. 運動合併症とその対応
    　　D. ウェアリング・オフの治療
    　　E. No on, delayed onの治療
    　　F. 早朝ジストニアの治療
    　　G. 血中濃度最高時ジスキネジアの治療
    　　H. 二相性ジスキネジアの治療
    　　　Case Study
    　■2．すくみ足
    　　A. すくみ足とは
    　　B. すくみ足の増悪に関連する諸因子
    　　C. すくみ足と転倒
    　　D. すくみ足の分類と治療
    　　E. すくみ足に対する治療
    　　F. 薬物治療
    　　G. 外的cueの導入
    　　H. 音楽療法
    　　I. すくみ足に対するリハビリテーション
    　　　Case Study
    　■3．姿勢保持障害とその対策
    　　A. パーキンソン病の進行と姿勢保持障害
    　　B. 姿勢保持障害の神経機構
    　　C. 姿勢保持障害の対策
    　　D. 姿勢保持障害と転倒
    　　E. 転倒による外傷・骨折の予防
    　　F. 姿勢保持障害，転倒の治療・対策アルゴリズム
    　　　Case Study
    　■4．姿勢異常とその対策
    　　A. 前屈姿勢
    　　B. 腰曲り
    　　C. 体幹側屈（斜め徴候，Pisa 症候群）
    　　D. 首下がり
    　　E. 上下肢における異常姿位

    ■VI　外科治療
    　■1．定位脳手術
    　　A. 手術適応
    　　B. ターゲット選択
    　　C. DBS装置
    　　D. 手術の概略
    　　E. 合併症
    　■2．術後の調整・管理
    　　A. 術後早期の管理
    　　B. 慢性期の管理
    　　C. 術後の注意点

    ■VII　非運動症状とその治療
    　■1．認知機能障害とその対策
    　　A. パーキンソン病における認知症の疫学
    　　B. パーキンソン病における認知症の臨床像
    　　C. 軽度認知機能障害を伴うパーキンソン病の臨床像
    　　D. パーキンソン病における認知機能障害の病理学的背景
    　　E. レビー小体型認知症との関連
    　　F. PDDにおける神経化学システムの異常
    　　G. PDDの治療
    　　H. パーキンソン病における認知症の発症予測に向けて
    　■2．精神症状とその対策（気分障害，幻覚・妄想，行動障害）
    　　A. 気分障害
    　　B. 幻覚・妄想
    　　　Case Study
    　　C. 衝動制御障害・ドパミン調節障害
    　■3．睡眠障害とその対策
    　　A. 不眠
    　　B. REM睡眠行動障害
    　　C. 下肢静止不能症候群
    　　D. 日中の過度の眠気
    　　E. 突発的睡眠
    　■4．自律神経障害とその対策
    　　A. 消化器症状
    　　B. 心血管系障害
    　　C. 神経因性膀胱
    　　D. 性機能障害
    　　E. 発汗障害
    　■5．感覚障害とその対策（嗅覚障害，痛み）
    　　A. 嗅覚障害
    　　B. 痛み
    　■6．流涎・嚥下障害，構音障害とその対策
    　　A. 流涎
    　　B. 嚥下障害
    　　C. 構音障害

    ■VIII　リハビリテーション
    　■1．PDの障害構造
    　　A. 運動障害
    　　B. 自律神経障害
    　　C. 精神機能障害
    　　D. 転倒・転落
    　　E. L-ドパ長期連用時の障害
    　　F. その他
    　■2．PDのリハ評価方法
    　■3．PDのリハアプローチ
    　　A. Stage I〜II
    　　B. Stage III
    　　C. Stage IV
    　　D. Stage V

    ■IX　社会資源の活用（難病法，障害者自立支援法，介護保険法）
    　■1．医療制度
    　　A. 指定難病の医療費助成制度
    　■2．所得補償
    　　A. 傷病手当
    　　B. 障害年金
    　　C. 特別障害者手当
    　■3．生活支援
    　　A. 身体障害者手帳
    　　B. 介護保険法
    　　C. 障害者総合支援法

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

[I] パーキンソン病とはどのような病気か

P.14 掲載の参考文献
1) 武田篤. パーキンソン病の病因・病態生理. 山本光利, 編. GP・レジデントのためのパーキンソン病テキストブック. 東京 : アルタ出版 ; 2012. p.30-9.
 
2) 菊池昭夫, 武田篤. 病態生理-無動, 固縮, 振戦, 姿勢反射障害-. 特集 : パーキンソン病-基礎・臨床研究のアップデート. 日本臨牀. 2009 ; 67 (増刊号 4) : 133-8.
 

[II] 診断について

P.23 掲載の参考文献
1) Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 ; 51 : 745-52.
 
2) Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 ; 30 : 1591-601.
PubMed
3) 「パーキンソン病治療ガイドライン」作成委員会, 編. 日本神経学会, 監. パーキンソン病診療ガイドライン 2018. 東京 : 医学書院 ; 2018.
 
P.30 掲載の参考文献
1) 菊池昭夫, 武田篤. パーキンソン病の嗅覚低下. 神経内科. 2007 ; 66 : 72-7.
 
2) Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res. 2006 ; 16 : 46-54.
PubMed
3) Becker G, Seufert J, Bogdahn U, et al. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology. 1995 ; 45 : 182-4.
PubMed
4) Schwingenschuh P, Ruge D, Edwards MJ, et al. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease : a clinical and electrophysiological study. Mov Disord. 2010 ; 25 : 560-9.
PubMed
P.38 掲載の参考文献
1) Massano J, Bhatia KP. Clinical approach to Parkinson's disease : features, diagnosis, and principles of management. Cold Spring Harb Perspect Med. 2012 ; 2 : a008870.
PubMed
2) Kosaka K, Oyanagi S, Matsushita M, et al. Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol. 1976 ; 36 : 221-33.
PubMed
3) Williams DR, Holton JL, Strand K, et al. Pure akinesia with gait freezing : a third clinical phenotype of progressive supranuclear palsy. Mov Disord. 2007 ; 22 : 2235-41.
PubMed
4) Boeve BF. The multiple phenotypes of corticobasal syndrome and corticobasal degeneration : implications for further study. J Mol Neurosci. 2011 ; 45 : 350-3.
PubMed
5) Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007 ; 22 : 2210-5.
PubMed

[III] 主なパーキンソン病治療薬のまとめ

P.52 掲載の参考文献
1) Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007 ; 22 : 2409-17.
PubMed
2) Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease : A randomized controlled trial. JAMA. 2000 ; 284 : 1931-8.
 
3) Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study. Mov Disord. 2006 ; 21 : 343-53.
 
4) Bracco F, Battaglia A, Chouza C, et al. PKDS009 Study Group. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease : final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004 ; 18 : 733-46.
 
5) Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update : pharmacological and surgical treatments of Parkinson's disease : 2001 to 2004. Mov Disord. 2005 ; 20 : 523-39.
PubMed
6) Fox SH, Katzenschlager R, Lim SY, et al. The movement disorder society evidence-based medicine review update : Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 ; 26 : S2-41.
PubMed
7) PD Med Collaborative Group, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED) : a large, openlabel, pragmatic randomised trial. Lancet. 2014 ; 384 : 1196-205.
 
8) Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010 ; 25 : 2649-53.
PubMed
9) Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008 ; 359 : 2468-76.
PubMed
10) Olanow CW, Kieburtz K, Odin P, et al. LCIG horizon study group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease : a randomised, controlled, double-blind, doubledummy study. Lancet Neurol. 2014 ; 13 : 141-9.
 
11) Antonini A, Yegin A, Preda C, et al. GLORIA study investigators and coordinators. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients ; 12-month interim outcomes. Parkinsonism Relat Disord. 2015 ; 21 : 231-5.
 
12) Devos D. French DUODOPA Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord. 2009 ; 24 : 993-1000.
 
13) Rasmussen VG, Stergaard K, Dupont E, et al. The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists. Mov Disord. 2011 ; 26 : 801-6.
 
14) Zhou CQ, Zhang JW, Wang M, et al. Meta-analysis of the efficacy and safety of long-acting non-ergot dopamine agonists in Parkinson's disease. Clin Neurosci. 2014 ; 21 : 1094-101.
PubMed
15) Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease : metaanalysis of randomized controlled trials. Drug Saf. 2010 ; 33 : 147-61.
PubMed
16) Watts RL, Lyons KE, Pahwa R, et al ; 228 Study Investigators. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord. 2010 ; 25 : 858-66.
PubMed
17) Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease. a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 ; 9 : 573-80.
PubMed
18) Hauser RA, Schapira AH, Barone P, et al. Pramipexole ER Studies Group. Longterm safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. Eur J Neurol. 2014 ; 21 : 736-43.
PubMed
19) Mizuno Y, Nomoto M, Hasegawa K, et al. Rotigotine Trial Group. Rotigotine vs ropinirole in advanced stage Parkinson's disease : a double-blind study. Parkinsonism Relat Disord. 2014 ; 20 : 1388-93.
PubMed
20) Trenkwalder C, Kies B, Rudzinska M, et al. Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease : a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011 ; 26 : 90-9.
 
21) Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy : a multicentre study. J Neurol Neurosurg Psychiatry. 2014 ; 85 : 840-4.
PubMed
22) Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease : an evidence-based comparison. Drugs Aging. 2003 ; 20 : 847-55.
PubMed
23) Brunt ER, Brooks DJ, Korczyn AD, et al ; 043 Study Group. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm. 2002 ; 109 : 489-502.
 
24) Mizuno Y, Yanagisawa N, Kuno S, et al. Japanese Pramipexole Study Group. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord. 2003 ; 18 : 1149-56.
 
25) Ikebe S, Harada T, Hashimoto T, et al. Prevention and treatment of malignant syndrome in Parkinson's disease : a consensus statement of the malignant syndrome research group. Parkinsonism Relat Disord. 2003 ; 9 Suppl 1 : S47-9. Review.
 
26) Shoulson I, Oakes D, Fahn S, et al. Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease. a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol. 2002 ; 51 : 604-12.
 
27) Olanow CW, Rascol O, Hauser R, et al ; ADAGIO Study Investigators. A doubleblind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 ; 361 : 1268-78.
 
28) Mizuno Y, Kanazawa I, Kuno S, et al. Placebo-controlled, double-blind dosefinding study of entacapone in fluctuating parkinsonian patients. Mov Disord. 2007 ; 22 : 75-80.
PubMed
P.63 掲載の参考文献
1) Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease : an in vivo positron emission tomographic study. Arch Neurol. 2003 ; 60 : 1745-8.
 
2) Fox SH. Non-dopaminergic treatments for motor control in Parkinson's disease. Drugs. 2013 ; 73 : 1405-15.
PubMed
3) Thomas A, Iacono D, Luciano AL, et al. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004 ; 75 : 141-3.
PubMed
4) Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease : the AMANDYSK trial. Neurology. 2014 ; 82 : 300-7.
PubMed
5) Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des. 2004 ; 10 : 687-93.
PubMed
6) Yamamura S, Ohoyama K, Nagase H, et al. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology. 2009 ; 57 : 322-31.
PubMed
7) Fukuyama K, Tanahashi S, Hoshikawa M, et al. Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway. Neuropharmacology. 2014 ; 76 Pt A : 137-45.
 
8) Goldstein DS. L-Dihydroxyphenylserine (L-DOPS) : a norepinephrine prodrug. Cardiovasc Drug Rev. 2006 ; 24 : 189-203.
PubMed
9) Tohgi H, Abe T, Takahashi S. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J Neural Transm Park Dis Dement Sect. 1993 ; 5 : 27-34.
PubMed
10) Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord. 2015 ; 30 : 646-54. doi : 10.1002/mds.26086. Epub 2014 Dec 9.
 
11) Kondo T, Mizuno Y ; Japanese Istradefylline Study Group. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease. Clin Neuropharmacol. 2015 ; 38 : 41-6.
 
12) Svenningsson P, Hall H, Sedvall G, et al. Distribution of adenosine receptors in the postmortem human brain : an extended autoradiographic study. Synapse. 1997 ; 27 : 322-35.
 

[IV] 初期治療

P.72 掲載の参考文献
1) 中島健二, 和田健二, 植村佑介, 他. 我が国におけるパーキンソン病の疫学研究. 日本臨牀. 2009 ; 67 (増刊号 4 パーキンソン病 : 基礎・臨床研究のアップデート) : 19-23.
 
2) Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. 2006 ; 5 : 75-86.
PubMed
3) Kempster PA, O'Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson's disease : a clinico-pathological study. Brain. 2010 ; 133 (Pt 6) : 1755-62.
 
4) Grover S, Somaiya M, Kumar S, et al. Psychiatric aspects of Parkinson's disease. J Neurosci Rural Pract. 2015 ; 6 : 65-76.
PubMed
5) McKeith IG, Boeve BF, Dickson DW, et al. Dignosis and management of dementia with Lewy bodies. Neurology. 2017 ; 89 : 1-13.
 
6) de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006 ; 5 : 525-35.
PubMed
7) Ross GW, Abbott RD, Petrovitch H, et al. Relationship between caffeine intake and Parkinson disease. JAMA. 2000 ; 284 : 1378-9.
PubMed
8) Chen H, O'Reilly E, McCullough ML, et al.Consumption of dairy products and risk of Parkinson's disease. Am J Epidemiol. 2007 ; 165 : 998-1006. Epub 2007 Jan 31.
 
9) Hashimoto T, Tokuda T, Hanyu N, et al. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease. Parkinsonism Relat Disord. 2003 ; 9 suppl 1 : S25-S30.
 
P.74 掲載の参考文献
1) 日本神経学会, 監. パーキンソン病診療ガイドライン 2018. 東京 : 医学書院 : 2018.
 
2) Fahn S, Oakes D, Shoulson I, et al ; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 ; 351 : 2498-508.
 
3) Shoulson I. DATATOP : a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann Neurol. 1998 ; 44 (3 Suppl 1) : S160-6.
 
4) Hauser RA, Lew MF, Hurtig HI, et al. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord. 2009 ; 24 : 564-73.
PubMed
P.85 掲載の参考文献
1) Fahn S, Oakes D, Shoulson I, et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 ; 351 : 2498-508.
 
2) Goetz CG, Poewe W, Rascol O, et al. Evidence-based medical review update : pharmacological and surgical treatments of Parkinson's disease : 2001 to 2004. Mov Disord. 2005 ; 20 : 523-39.
PubMed
3) Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study. Mov Disord. 2006 ; 21 : 343-53.
 
4) 日本神経学会, 監. パーキンソン病治療ガイドライン 2018. 東京 : 医学書院 ; 2018. p.107.
 
5) PD Med Collaborative Group, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED) : a large, openlabel, pragmatic randomised trial. Lancet. 2014 ; 384 : 1196-205.
 

[V] 進行期治療

P.105 掲載の参考文献
1) Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 ; 351 : 2498-508.
PubMed
2) Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain. 2000 ; 123 : 2297-305.
PubMed
3) Fox SH, Katzenschlager R, Lim SY, et al. The Movement Disorder Society Evidence-based Medicine Review Update : Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 ; 26 : S2-41.
PubMed
4) PD Med Collaborative Group, Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED) : a large, open-label, pragmatic randomised trial. Lancet. 2014 ; 384 : 1196-205.
 
5) Olanow CW, Kieburtz K, Odin P, et al. LCIG Horizon Study Group. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease : a randomised, controlled, double-blind, doubledummy study. Lancet Neurol. 2014 ; 13 : 141-9.
 
6) Schuepbach WM, Rau J, Knudsen K, et al. EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013 ; 368 : 610-22.
 
7) Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease : severity and correlation with motor complications. Neurology. 2013 ; 80 : 800-9.
PubMed
8) Stowe R, Ives N, Clarke CE, et al. Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease. Mov Disord. 2011 ; 26 : 587-98.
PubMed
9) Lee WY, Yoon WT, Shin HY, et al. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord. 2008 ; 23 : 1696-700.
PubMed
10) 西川典子, 永井将弘, 久保円, 他. 経口摂取不可のParkinson病治療薬の検討. 神経治療. 2011 ; 28 : 677-80.
 
11) Kim HJ, Lee JY, Kim JY, et al. Effect of bilateral subthalamic deep brain stimulation on diphasic dyskinesia. Clin Neurol Neurosurg. 2008 ; 110 : 328-32.
PubMed
P.119 掲載の参考文献
1) Okuma Y, Yanagisawa N. The clinical spectrum of freezing of gait in Parkinson's disease. Mov Disord. 2008 ; 23 : S426-30.
PubMed
2) Pastor MA, Artieda J, Jahanshahi M, et al. Time estimation and reproduction is abnormal in Parkinson's disease. Brain. 1992 ; 115 : 211-25.
PubMed
3) Marsden CD. The mysterious motor function of the basal ganglia : the Robert Wartenberg Lecture. Neurology. 1982 ; 32 : 514-39.
 
4) Freeman JS, Cody FW, Schady W. The influence of external timing cues upon the rhythm of voluntary movements in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1993 ; 56 : 1078-84.
PubMed
5) Latt MD, Lord SR, Morris JG, et al. Clinical and physiological assessments for elucidating falls risk in Parkinson's disease. Mov Disord. 2009 ; 24 : 1280-9.
PubMed
6) Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease : A randomized controlled trial. JAMA. 2000 ; 284 : 1931-8.
 
7) Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007 ; 22 : 2409-17.
PubMed
8) Romito LM, Contarino MF, Vanacore N, et al. Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease : longterm observation. Mov Disord. 2009 ; 24 : 557-63.
PubMed
9) Fukada K, Endo T, Yokoe M, et al. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson's disease. Med Hypotheses. 2013 ; 80 : 209-12.
PubMed
10) Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease : the RESCUE trial. J Neurol Neurosurg Psychiatry. 2007 ; 78 : 134-40.
 
11) Enzensberger W, Fischer PA. Metronome in Parkinson's disease. Lancet. 1996 ; 347 : 1337.
PubMed
12) de Dreu MJ, van der Wilk AS, Poppe E, et al. Rehabilitation, exercise therapy and music in patients with Parkinson's disease : a meta-analysis of the effects of music-based movement therapy on walking ability, balance and quality of life. Parkinsonism Relat Disord. 2012 ; 18 : S114-9.
 
13) Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev. 2013 ; 10 : CD002817.
 
14) Li F, Harmer P, Liu Y, et al. A randomized controlled trial of patient-reported outcomes with tai chi exercise in Parkinson's disease. Mov Disord. 2014 ; 29 : 539-45.
 
P.131 掲載の参考文献
1) Hunt AL, Sethi KD. The pull test : a history. Mov Disord. 2006 ; 21 : 894-9.
 
2) Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Societysponsored revision of the Unified Parkinson's Disease Rating Scale (MDSUPDRS) : Process, format, and clinimetric testing plan. Mov Disord. 2007 ; 22 : 41-7.
PubMed
3) Hoehn MM, Yahr MD. Parkinsonism : onset, progression and mortality. Neurology 1967 ; 17 : 427-42.
PubMed
4) 高草木薫. 脚橋被蓋核 (PPN) の機能とParkinson病. 神経内科. 2014 ; 80 : 527-35.
 
5) Montero-Odasso M, Verghese J, Beauchet O, et al. Gait and cognition : a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012 ; 60 : 2127-36.
PubMed
6) Berdot S, Bertrand M, Dartigues JF, et al. Inappropriate medication use and risk of falls : a prospective study in a large community-dwelling elderly cohort. BMC Geriatr. 2009 ; 9 : 30.
 
7) Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998 ; 339 : 875-82.
PubMed
8) Bloem BR, Hausdorff JM, Visser JE, et al. Falls and freezing of gait in Parkinson's disease : a review of two interconnected, episodic phenomena. Mov Disord. 2004 ; 19 : 871-84.
 
9) Huang YF, Cherng YG, Hsu SP, et al. Risk and adverse outcomes of fractures in patients with Parkinson's disease : two nationwide studies. Osteoporos Int. 2015 ; 26 : 1723-32.
PubMed
10) Bloem BR, van Vugt JP, Beckley DJ. Postural instability and falls in Parkinson's disease. Adv Neurol. 2001 ; 87 : 209-23.
PubMed
11) Chung KA, Lobb BM, Nutt JG, et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology. 2010 ; 75 : 1263-9.
PubMed
12) Henderson EJ, Lord SR, Brodie MA, et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD) : a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 ; 15 : 249-58.
PubMed
13) Latt MD, Lord SR, Morris JG, et al. Clinical and physiological assessments for elucidating falls risk in Parkinson's disease. Mov Disord. 2009 ; 24 : 1280-9.
PubMed
14) Critchley RJ, Khan SK, Yarnall AJ, et al. Occurrence, management and outcomes of hip fractures in patients with Parkinson's disease. Br Med Bull. 2015 ; 115 : 135-42.
PubMed
P.144 掲載の参考文献
1) Benninger F, Khlebtovsky A, Roditi Y, et al. Beneficial effect of levodopa therapy on stooped posture in Parkinson's disease. Gait Posture. 2015. pii : S0966-6362 (15) 00475-0
 
2) Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006 ; 21 : 1856-63.
PubMed
3) Tiple D, Fabbrini G, Colosimo C, et al. Camptocormia in Parkinson disease : an epidemiological and clinical study. J Neurol Neurosurg Psychiatry. 2009 ; 80 : 145-8.
PubMed
4) Abe K, Uchida Y, Notani M. Camptocormia in Parkinson's disease. Parkinsons Dis. 2010 ; pii : 267640.
 
5) Seki M, Takahashi K, Koto A, et al. Camptocormia in Japanese patients with Parkinson's disease : a multicenter study. Mov Disord. 2011 ; 26 : 2567-71.
PubMed
6) Furusawa Y, Hanakawa T, Mukai Y, et al. Mechanism of camptocormia in Parkinson's disease analyzed by tilt table-EMG recording. Parkinsonism Relat Disord. 2015 ; 21 : 765-70.
PubMed
7) Srivanitchapoom P, Hallett M. Camptocormia in Parkinson's disease : definition, epidemiology, pathogenesis and treatment modalities. J Neurol Neurosurg Psychiatry. 2015. pii : jnnp-2014-310049.
 
8) Kashihara K, Imamura T. Clinical correlates of anterior and lateral fexion of the thoracolumbar spine and dropped head in patients with Parkinson's disease. Parkinsonism Relat Disord. 2012 ; 18 : 290-3.
 
9) Nakane S, Yoshioka M, Oda N. The characteristics of camptocormia in patients with Parkinson's disease : A large cross-sectional multicenter study in Japan. J Neurol Sci. 2015 ; 358 : 299-303.
PubMed
10) Yamane Y, Kimura F, Unoda K, et al. Postural abnormality as a risk marker for leg deep venous thrombosis in PD. PLoS One. 2013 ; 8 : e66984.
 
11) Galati S, Moller JC, Stadler C. Ropinirole-induced Pisa syndrome in Parkinson disease. Clin Neuropharmacol. 2014 ; 37 : 58-9.
PubMed
12) Nakayama Y, Miwa H. Drug-induced camptocormia : a lesson regarding vascular Parkinsonism. Intern Med. 2012 ; 51 : 2843-4.
PubMed
13) Vela L, Jimenez Moron D, Sanchez C, et al. Camptocormia induced by atypical antipsychotics and resolved by electroconvulsive therapy. Mov Disord. 2006 ; 21 : 1977-80.
PubMed
14) Miyaoka T, Seno H, Yamamori C, et al. Pisa syndrome due to a cholinesterase inhibitor (donepezil) : a case report. J Clin Psychiatry. 2001 ; 62 : 573-4.
PubMed
15) Nieves AV, Miyasaki JM, Lang AE. Acute onset dystonic camptocormia caused by lenticular lesions. Mov Disord. 2001 ; 16 : 177-80.
PubMed
16) Wrede A, Margraf NG, Goebel HH, et al. Myofibrillar disorganization characterizes myopathy of camptocormia in Parkinson's disease. Acta Neuropathol. 2012 ; 123 : 419-32.
PubMed
17) Eskow Jaunarajs KL, Bonsi P, Chesselet MF, et al. Striatal cholinergic dysfunction as a unifying theme in the pathophysiology of dystonia. Prog Neurobiol. 2015 ; 127-128 : 91-107.
 
18) Schulz-Schaeffer WJ, Margraf NG, Munser S, et al. Effect of neurostimulation on camptocormia in Parkinson's disease depends on symptom duration. Mov Disord. 2015 ; 30 : 368-72.
PubMed
19) Doherty KM, van de Warrenburg BP, Peralta MC, et al. Postural deformities in Parkinson's disease. Lancet Neurol. 2011 : 538-49.
PubMed
20) Ye BK, Kim HS, Kim YW. Correction of camptocormia using a cruciform anterior spinal hyperextension brace and back extensor strengthening exercise in a patient with Parkinson disease. Ann Rehabil Med. 2015 ; 39 : 128-32.
 
21) Ekbom K, Lindholm H, Ljungberg L. New dystonic syndrome associated with butyrophenone therapy. Z Neurol. 1972 ; 202 : 94-103.
PubMed
22) Cannas A, Solla P, Floris G, et al. Reversible Pisa syndrome in Parkinson's disease during treatment with pergolide : a case report. Clin Neuropharmacol. 2005 ; 28 : 252.
PubMed
23) Yokochi F. Lateral flexion in Parkinson's disease and Pisa syndrome. J Neurol. 2006 ; 253 Suppl 7 : VII17-20.
 
24) Umemura A, Oka Y, Ohkita K, et al. Effect of subthalamic deep brain stimulation on postural abnormality in Parkinson disease. J Neurosurg. 2010 ; 112 : 1283-8.
PubMed

[VI] 外科治療

P.168 掲載の参考文献
1) Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg. 1992 ; 76 : 53-61.
PubMed
2) Benabid AL, Pollak P, Louveau A, et al. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol. 1987 ; 50 : 344-6.
PubMed
3) Parsons TD, Rogers SA, Braaten AJ, et al. Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease : a meta-analysis. Lancet Neurol. 2006 ; 5 : 578-88.
PubMed
4) Denheyer M, Kiss ZH, Haffenden AM. Behavioral effects of subthalamic deep brain stimulation in Parkinson's disease. Neuropsychologia. 2009 ; 47 : 3203-9.
PubMed
5) Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013 ; 368 : 610-22.
PubMed

[VII] 非運動症状とその治療

P.180 掲載の参考文献
1) 武田篤. Parkinson's disease dementia. 認知症学 (下). 1012 : 日本臨牀. 2011 ; 12.
 
2) Hely MA, Reid WGJ, Adena MA, et al. The Sydney multicenter study of Parkinson's disease : the inevitability of dementia at 20 years. Movement Disorders : Official Journal of the Movement Disorder Society. 2008 ; 23 : 837-44.
PubMed
3) Obeso JA, Rodriguez-Oroz MC, Stamelou M, et al. The expanding universe of disorders of the basal ganglia. Lancet. 2014 ; 384 : 523-31.
PubMed
4) Abe Y, Kachi T, Kato T, et al. Occipital hypoperfusion in Parkinson's disease without dementia : correlation to impaired cortical visual processing. Journal of Neurology, Neurosurgery, and Psychiatry. 2003 ; 74 : 419-22.
PubMed
5) Hosokai Y, Nishio Y, Hirayama K, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson's disease with and without mild cognitive impairment. Movement disorders : Official Journal of the Movement Disorder Society. 2009 ; 24 : 854-62.
PubMed
6) Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease : Movement Disorder Society Task Force guidelines. Mov Disord. 2012 ; 27 : 349-56.
PubMed
7) Kalbe E, Rehberg SP, Heber I, et al. Subtypes of mild cognitive impairment in patients with Parkinson's disease : evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry. 2016 ; 87 : 1099-105.
PubMed
8) Williams-Gray CH, Evans JR, et al. The distinct cognitive syndromes of Parkinson's disease : 5 year follow-up of the CamPaIGN cohort. Brain. 2009 ; 132 : 2958-69.
PubMed
9) Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease : 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry. 2013 ; 84 : 1258-64.
 
10) Shoji Y, Nishio Y, Baba T, et al. Neural substrates of cognitive subtypes in Parkinson's disease : a 3-year longitudinal study. PLoS One. 2014 ; 9 : e110547.
PubMed
11) Baba T, Hosokai Y, Nishio Y, et al. Longitudinal study of cognitive and cerebral metabolic changes in Parkinson's disease. J Neurol Sci. 2017 ; 372 : 288-93.
PubMed
12) Baba T, Kikuchi A, Hirayama K, et al. Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson's disease : a 3 year longitudinal study. Brain. 2012 ; 135 : 161-9.
PubMed
13) Baba T, Takeda A, Kikuchi A, et al. Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. Mov Disord. 2011 ; 26 : 621-8.
PubMed
P.202 掲載の参考文献
1) パーキンソン病診療ガイドライン作成委員会, 編. 日本神経学会, 監修. パーキンソン病診療ガイドライン 2018. 東京 : 医学書院. 2018 ; p.248.
 
2) Khoo TK, Yarnall AJ, Gordon WD, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013 ; 80 : 276-81.
 
3) Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson's disease : a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013 ; 84 : 14-7.
PubMed
4) Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord. 2009 ; 24 : 1333-8.
PubMed
5) den Brok MG, van Dalen JW, van Gool WA, et al. Apathy in Parkinson's disease : A systematic review and meta-analysis. Mov Disord. 2015 ; 30 : 759-69.
PubMed
6) Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease. Arch Neurol. 2003 ; 60 : 1745-8.
PubMed
7) Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease : a cross-sectional study of 3,090 patients. Arch Neurol. 2010 ; 67 : 589-95.
 
8) Pettorruso M, Fasano A, De Risio L, et al. Punding in non-demented Parkinson's disease patients : Relationship with psychiatric and addiction spectrum comorbidity. J Neurol Sci. 2016 ; 362 : 344-7.
PubMed
9) Warren N, O'Gorman C, Lehn A, et al. Dopamine dysregulation syndrome in Parkinson's disease : a systematic review of published cases. J Neurol Neurosurg Psychiatry. 2017 ; 88 : 1060-4.
 
10) Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease : its relation to the dopamine dysregulation syndrome. Mov Disord. 2004 ; 19 : 397-405.
 
11) Samuel M, Rodriguez-Oroz M, Antonini A, et al. Management of impulse control disorders in Parkinson's disease : controversies and future approaches. Mov Disord. 2015 ; 30 : 150-9.
PubMed
12) Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol. 2010 ; 67 : 58-63.
PubMed
P.209 掲載の参考文献
1) American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL : American Academy of Sleep Medicine ; 2014.
 
2) Postuma RB, Arnulf I, Hogl B, et al. A single-question screen for rapid eye movement sleep behavior disorder : a multicenter validation study. Mov Disord. 2012 ; 27 : 913-6.
PubMed
3) Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med. 2011 ; 12 : 445-53.
 
4) Miyamoto T, Miyamoto M, Iwanami M, et al. The REM sleep behavior disorder screening questionnaire : validation study of a Japanese version. Sleep Med. 2009 ; 10 : 1151-4.
PubMed
5) Sasai T, Matsuura M, Wing YK, et al. Validation of the Japanese version of the REM sleep behavior disorder questionnaire (RBDQ-JP). Sleep Med. 2012 ; 13 : 913-8.
PubMed
6) Braak H, Del Treidici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiolo Aging. 2003 ; 24 : 197-211.
 
7) International Restless Legs Syndrome Study Group. 2012 Revised IRLSSG Diagnostic Criteria for RLS. <http://irlssg.org/diagnostic-criteria/>, accessed on April, 16, 2015.
 
8) 福原俊一, 竹上未紗, 鈴鴨よしみ, 他. 日本語版the Epworth Sleepiness Scale (JESS) ～これまで使用されていた多くの「日本語版」との主な差異と改訂～. 日本呼吸器学会誌. 2006 ; 44 : 896-8.
 
P.219 掲載の参考文献
1) Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015 ; 386 : 896-912.
PubMed
2) Pfeiffer RF. Management of autonomic dysfunction in Parkinson's disease. Semin Neurol. 2017 ; 176-85.
PubMed
3) De Pablo-Fernandez E, Tur C, Revesz T, et al. Association of autonomic dysfunction with disease progression and survival in Parkinson disease. JAMA Neurol. 2017 ; 74 : 970-6.
PubMed
4) Barboza JL, Okun MS, Moshiree B. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinson's disease. Expert Opin Pharmacother. 2015 ; 16 : 2449-64.
PubMed
5) Fasano A, Visanji NP, Liu LW, et al. Gastrointestinal dysfunction in Parkinson's disease. Lancet Neurol. 2015 ; 14 : 625-39.
PubMed
6) Espay AJ, LeWitt PA, Hauser RA, et al. Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies : prioritisation of treatment targets. Lancet Neurol. 2016 ; 15 : 954-66.
PubMed
7) Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017 ; 264 : 1567-82
 
8) Eschlbock S, Wenning G, Fanciulli A. Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. J Neural Transm. 2017 ; 124 : 1567-605.
PubMed
9) Sakakibara R, Panicker J, Finazzi-Agro E, et al. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn. 2016 ; 35 : 551-63.
PubMed
10) Sakakibara R, Uchiyama T, Yamanishi T, et al. Genitourinary dysfunction in Parkinson's disease. Mov Disord. 2010 ; 25 : 2-12.
PubMed
11) 斎藤博, 木暮久也. パーキンソン病における温熱発汗機能異常. 臨床神経. 1989 ; 29 : 734-40.
 
P.228 掲載の参考文献
1) Langston JW. The Parkinson's complex : parkinsonism is just the tip of the iceberg. Ann Neurol. 2006 ; 59 : 591-6.
PubMed
2) 馬場徹, 菊池昭夫, 長谷川隆文, 他. Parkinson病の運動症状発症に先行する非運動症状-嗅覚障害-. 神経内科. 2011 ; 75 : 319-23.
 
3) Kawasaki I, Baba T, Takeda A, et al. Loss of awareness of hyposmia is associated with mild cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord. 2016 ; 22 : 74-9.
PubMed
4) Kikuchi A, Baba T, Takeda A. Differentiating Parkinson's disease from multiple system atrophy by [123I] meta-iodobenzylguanidine myocardial scintigraphy and olfactory test. Parkinsonism & related disorders. 2011.
PubMed
5) Berendse HW, Booij J, Francot CM, et al. Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol. 2001 ; 50 : 34-41.
PubMed
6) Baba T, Takeda A, Kikuchi A, et al. Association of olfactory dysfunction and brain. Metabolism in Parkinson's disease. Mov Disord. 2011 ; 26 : 621-8.
PubMed
7) Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain. 2010 ; 133 (Pt 6) : 1747-54.
 
8) Wasner G, Deuschl G. Pains in Parkinson disease--many syndromes under one umbrella. Nat Rev Neurol. 2012 ; 8 : 284-94.
PubMed
9) Ha AD, Jankovic J. Pain in Parkinson's disease. Mov Disord. 2012 ; 27 : 485-91.
PubMed
P.232 掲載の参考文献
1) 朝比奈正人, 服部孝道. パーキンソン病の自律神経症状. Clin Neurosci. 2007 ; 25 : 51-3.
 
2) Kalf JG, Bloem BR, Munneke M. Diuranl and nocturnal drooling in Parkinson's disease. J Neurol. 2012 ; 259 : 119-23.
 
3) South AR, Somers SM, Jog MS. Gum chewing improve swallow frequency and latency in Parkinson patients : a preliminary study. Neurology. 2010 ; 74 : 1198-202.
PubMed
4) Hunter PC, Crameri J, Austin S, et al. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry. 1997 ; 63 : 579-83.
PubMed
5) Qualman SJ, Haupt HM, Yang P, et al. Esophagial Lewy bodies associated with ganglion cell loss in achalasia : similarity to Parkinson's disease. Gastroenterology. 1984 ; 87 : 848-56.
 
6) Barke GS, Gerratt B, Kreiman J, et al. Treatment of Parkinson hypophonia with percutaneous collagen augumentation. Laryngoscope. 1999 ; 109 : 1295-9.
 

[VIII] リハビリテーション

P.266 掲載の参考文献
1) 花山耕三. 神経・筋疾患-パーキンソン病. In : 千野直一, 編. 現代リハビリテーション医学. 改訂第3版. 東京 : 金原出版. 2009 ; p.399-401.
 
2) Hoehn MM, Yahr MD. Parkinsonism : Onset, progression, and mortality. Neurol. 1967 ; 17 : 427-42.
 
3) 長屋政博. パーキンソン病のリハビリテーション. In : 椿原彰夫, 編. 内科医のためのリハビリテーション. 東京 : 診断と治療社 ; 2002. p.117-28.
 
4) 立野勝彦. 神経筋疾患-パーキンソン病. In : 出江紳一, 他編. リハビリテーション医学テキスト. 改訂第3版. 東京 : 南江堂. 2010 ; p.190-3.
 
5) 関勝. 各疾患のリハビリテーション- パーキンソン病のリハビリテーション. In : 東洋療法学校協会, 編. リハビリテーション医学. 第4版. 東京 : 医歯薬出版 ; 2015. p.165-8.
 
6) 武田宜子. 障害とリハビリテーション看護. In : 武田宜子, 他編. 系統看護学講座-リハビリテーション看護. 東京 : 医学書院. 2006 ; p.80-9.
 
7) 長岡正範. 中枢神経機能障害 (運動障害) -パーキンソン病. In : 中村隆一, 他編. 入門 1) ハビリテーション医学. 第3版. 東京 : 医歯薬出版. 2007 ; p.653-60.
 
8) Petzinger GM, Fisher BE, McEwen S, et al. Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease. Lancet Neurol. 2013 ; 12 : 716-26.
PubMed
9) Chenkman M, Hall DA, Baron AE, et al. Exercise for people in early- or midstage Parkinson disease : a 16-month randomized controlled trial. Phys Ther. 2012 ; 92 : 1395-410.
PubMed
10) Duncan RP, Earhart GM. Randomized controlled trial of community-based dancing to modify disease progression in Parkinson disease. Neurorehabil Neural Repair. 2012 ; 26 : 132-43.
PubMed
11) Tambosco L, Percebois-Macadre L, Rapin A, et al. Effort training in Parkinson's disease : a systematic review. Ann Phys Rehabil Med. 2014 ; 57 : 79-104.
PubMed

書評

最近チェックした商品履歴

Loading...